Antiviral Medicine Could Help Halt Cognitive Decline in Early Alzheimer’s, Preliminary Data Show

Antiviral Medicine Could Help Halt Cognitive Decline in Early Alzheimer’s, Preliminary Data Show
Preliminary data from a Phase 2 study suggests that treating early Alzheimer’s disease patients who are positive for herpes simplex virus with an antiviral medicine may help halt their cognitive decline. Hugo Lövheim, MD, PhD, at Umeå University, Sweden, presented the results in a presentation titled “Valz Pilot Study – Valaciclovir treatment to individuals with early Alzheimer’s disease” at the 14th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, held March 26–31, in Lisbon, Portugal. Accumulating evidence, including a previous study from Lövheim’s team, shows that infection by the herpes simplex virus type 1 (HSV1) is linked with Alzheimer’s disease. These results suggest that antiviral medicines, such as valacyclovir (marketed as Valtrex, among other brand names) may benefit Alzheimer’s disease patients. To test the effects of valacyclovir, researchers are conducting a Phase 2 trial (NCT02997982) — called VALZ-Pilot — on 36 individuals with early Alzheimer’s disease, who have antibodies against HSV and carry the type 4 allele of the apoli
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *